TEMPEST THERAPEUTICS INC. - COMMON STOCK

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 16:21:02 By Nasdaq GlobeNewswire

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

12 Nov 2024 08:00:02 By Nasdaq GlobeNewswire

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

10 Oct 2024 07:01:00 By Nasdaq GlobeNewswire

Tempest Extends Limited Duration Stockholder Rights Plan

10 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20 Sep 2024 16:30:00 By Nasdaq GlobeNewswire

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

18 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

23 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

21 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

15 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 16:56:29 By Nasdaq GlobeNewswire

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

20 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

18 Jun 2024 18:22:51 By Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 Jun 2024 04:30:00 By Nasdaq GlobeNewswire

Tempest to Participate in Upcoming Investor Conferences

21 May 2024 08:00:00 By Nasdaq GlobeNewswire

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 16:29:27 By Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

26 Apr 2024 16:05:17 By Nasdaq GlobeNewswire

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

09 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

04 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Tempest Reports Year End 2023 Financial Results and Provides Business Update

19 Mar 2024 16:25:36 By Nasdaq GlobeNewswire